ESMO Asia 2016 Congress

Oncology Meeting Resources

16 Dec - 19 Dec 2016, Singapore

ESMO Asia 2016 Square

The ESMO Asia Congress comprised both scientific and educational tracks prepared by an international scientific committee. There was a strong emphasis on state of the art science, including a call for abstracts, and the current standard of care across all major tumour types.

Abstracts, presentations and webcasts from the ESMO Asia 2016 Congress are now available here to ESMO members. The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity.

Useful Links





Format available

http://oncologypro.esmo.org/Meeting-Resourc...patients-in-Korea-A-single-center-experience

BackgroundDecitabine have been used widely in the elderly AML patients, since the National Health Insurance system started to cover it in the November 2013 in Korea.

Date: 19 Dec 2016
Presenter: Hyewon Ryu
Resources: Abstract
Topics: Anti-Cancer Agents & Biologic Therapy, Leukaemia, Geriatric Oncology

http://oncologypro.esmo.org/Meeting-Resourc...cancer-in-a-high-middle-income-Asian-country

BackgroundCancer is an important driver of catastrophic expenditures. We examined the risk and predictors of financial catastrophe (FC) following cancer in Malaysia, an upper middle-income country with universal health coverage.

Date: 19 Dec 2016
Presenter: Nirmala Bhoo Pathy
Resources: Abstract
Topic: Bioethics, Legal, and Economic Issues

http://oncologypro.esmo.org/Meeting-Resourc...-for-recommending-expensive-anticancer-drugs

BackgroundOncologists and patients are frequently faced with difficult treatment decisions about expensive anticancer drugs. The aim of this study was to understand how different attributes of anticancer...

Date: 19 Dec 2016
Presenter: Deme Karikios
Resources: Abstract
Topics: Anti-Cancer Agents & Biologic Therapy, Bioethics, Legal, and Economic Issues

http://oncologypro.esmo.org/Meeting-Resourc...e-metastases-in-submucosal-colorectal-cancer

BackgroundIn colorectal cancer (CRC), the possibility of lymph node (LN) metastases is important to select the treatment. According to the Japanese Society for Cancer of the Colon and Rectum guidelines...

Date: 19 Dec 2016
Presenter: Shiki Fujino
Resources: Abstract
Topics: Colon Cancer, Rectal Cancer, Pathology/Molecular Biology

http://oncologypro.esmo.org/Meeting-Resourc...nalysis-of-the-phase-1-2-CheckMate-040-study

BackgroundMedian overall survival (OS) for first-line (1L) treatment of advanced hepatocellular carcinoma (aHCC) with sorafenib (sor) is up to 11 mo and 7–8 mo with best supportive care (BSC) post-sor failure.

Date: 19 Dec 2016
Presenter: Ignacio Melero
Resources: Abstract
Topics: Hepatobiliary Cancers, Cancer Immunology and Immunotherapy

http://oncologypro.esmo.org/Meeting-Resourc...ine-therapy-in-advanced-gastric-and-gastroes

BackgroundClaudin(CLDN)18.2 is a stomach specific tight junction protein. The chimeric monoclonal anti-CLDN18.2 antibody IMAB362 potently activates complement and antibody dependent cellular cytotoxicity.

Date: 19 Dec 2016
Presenter: Florian Lordick
Resources: Abstract
Topics: Drug Development, Gastric Cancer

http://oncologypro.esmo.org/Meeting-Resourc...ve-resection-of-metastatic-colorectal-cancer

BackgroundLymph node (LN) status is one of the most important predictors for M0 colorectal cancer patients. However, its clinical impact on stage IV colorectal cancer remains unclear.

Date: 19 Dec 2016
Presenter: Qingguo Li
Resources: Abstract
Topics: Colon Cancer, Rectal Cancer, Pathology/Molecular Biology, Surgery and/or Radiotherapy of Cancer